BML-259

• Description:

  BML-259 is a potent cyclin-dependent kinase 5 (Cdk5) inhibitor, with IC50s of 64 and 98 nM for Cdk5 and Cdk2, respectively[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/bml-259.html

• Concentration:

  10mM

• Purity:

  99.12

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=NC=C(C(C)C)S1)CC2=CC=CC=C2

• Molecular Formula:

  C14H16N2OS

• Molecular Weight:

  260.35

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Kaźmierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5) . Neurochem Int. 2011;58 (2) :206-214.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [267654-00-2]